Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imzokitug + pumitamig
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Imzokitug + pumitamig is a combination immunotherapy being developed by Bristol Myers Squibb for the treatment of first-line (1L) non-small cell lung cancer (NSCLC). Imzokitug (BMS-986322) is a recombinant interleukin-15 (IL-15) agonist, specifically a complex of IL-15 and the IL-15 receptor alpha (IL-15Rα) subunit, designed to stimulate the proliferation and activation of natural killer (NK) cells and CD8+ T cells. Pumitamig (BMS-986353) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an inhibitory immune checkpoint receptor expressed on T cells and NK cells. By combining an IL-15 agonist with a TIGIT inhibitor, the therapy aims to synergistically enhance the anti-tumor immune response by simultaneously providing a stimulatory signal to effector cells and blocking an inhibitory pathway that often limits their activity in the tumor microenvironment.
- Other names
- imzokitug + pumitamig
02
Targets
BTK (Bruton tyrosine kinase)CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on imzokitug + pumitamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imzokitug + pumitamig.